Astrazeneca (AZN) Receivables - Net (2016 - 2025)

Astrazeneca has reported Receivables - Net over the past 11 years, most recently at $15.2 billion for Q4 2025.

For Q4 2025, Receivables - Net rose 17.0% year-over-year to $15.2 billion; the TTM value through Dec 2025 reached $15.2 billion, up 17.0%, while the annual FY2025 figure was $15.2 billion, 17.0% up from the prior year.
Receivables - Net for Q4 2025 was $15.2 billion at Astrazeneca, up from $13.0 billion in the prior quarter.
Over five years, Receivables - Net peaked at $15.2 billion in Q4 2025 and troughed at -$1.5 billion in Q1 2021.
A 5-year average of $8.7 billion and a median of $9.0 billion in 2021 define the central range for Receivables - Net.
Biggest five-year swings in Receivables - Net: dropped 25.22% in 2022 and later soared 54.3% in 2024.
Year by year, Receivables - Net stood at $9.6 billion in 2021, then dropped by 25.22% to $7.2 billion in 2022, then rose by 16.57% to $8.4 billion in 2023, then soared by 54.3% to $13.0 billion in 2024, then rose by 17.0% to $15.2 billion in 2025.
Business Quant data shows Receivables - Net for AZN at $15.2 billion in Q4 2025, $13.0 billion in Q4 2024, and $8.4 billion in Q4 2023.

Peer Comparison